Search
for
Sort by
Research
300-330 / 1000+ resultsresearch Efficacy of Upadacitinib in Treating Alopecia Areata, Atopic Dermatitis, and Th1 Comorbidities in Pediatric Patients: A Comprehensive Case Series and Literature Review
Upadacitinib is safe and effective for treating alopecia areata and atopic dermatitis in children.
research CLINICAL MANAGEMENT OF PEMPHIGUS USING AZATHIOPRINE IN A LABRADOR RETRIEVER
A Labrador Retriever with pemphigus fully recovered after six weeks of azathioprine treatment.
research BH17 Bridging the gap: identifying dual-targeting therapies for patients with alopecia areata and coexisting immune-mediated inflammatory diseases
Dual-targeting therapies like Janus kinase inhibitors may treat both alopecia areata and other immune diseases.
research 708 SIG-1451: A topical anti-inflammatory new chemical entity for atopic dermatitis (AD)
SIG-1451 could be a promising new treatment for atopic dermatitis.
research Successful treatment of refractory folliculitis decalvans with secukinumab
Secukinumab effectively treated a difficult case of folliculitis decalvans.
research LB789 Novel IFNγ aptamer TAGX-0003 protected hair follicles from immune privilege collapse and reversed Alopecia Areata like phenotype in humanized mouse model
TAGX-0003 protected hair follicles and reversed alopecia areata in a mouse model.
research Case report: Dupilumab therapy for alopecia areata in a 4-year-old patient resistant to baricitinib
Dupilumab helped a 4-year-old grow hair back after another treatment failed.
research Uses of Dupilumab in Dermatology: A Systematic Review of the Randomized Controlled Trials
Dupilumab effectively improves skin conditions, reduces symptoms, and enhances quality of life in certain dermatological issues.
research Industry update: the latest developments in the field of therapeutic delivery, July 2018
New partnerships, clinical trials, and drug approvals marked progress in therapeutic delivery in July 2018.
research Cytokine-Targeting Biologic Therapies for Alopecia Areata: A Comprehensive Review of Mechanism of Action, Clinical Efficacy, and Adverse Events
Dupilumab and ustekinumab are promising treatments for alopecia areata, showing significant hair regrowth.
research Medicaid coverage of Janus kinase inhibitors for alopecia areata treatment
Medicaid coverage for alopecia areata treatments is inconsistent and often limited.
research Successful management of therapy-resistant chronic refractory atopic dermatitis and alopecia universalis with oral tofacitinib in a girl
Oral tofacitinib successfully treated a girl's severe skin and hair conditions.
research Low-dose tofacitinib for treating patients with severe alopecia areata: an efficient and cost-saving regimen
Low-dose tofacitinib is effective and cheaper for severe alopecia areata.
research A clinical study of pemphigus vulgaris and its variants, evaluation of safety and efficacy of glucocorticoids versus immunosuppressants at tertiary care hospital: a study of 75 cases
Combining glucocorticoids with immunosuppressants like cyclophosphamide improves remission and reduces relapse in pemphigus patients.
research Incidence and management of cutaneous toxicities associated with cetuximab
Cetuximab often causes skin rashes, and managing these is important for cancer treatment.
research Case report: pemphigus vulgaris in an adolescent
An 18-year-old girl with pemphigus vulgaris needed strong medication and careful treatment due to ineffective initial therapies and side effects.
research The effect of canakinumab on clinical outcomes in patients with COVID-19: A meta-analysis
Canakinumab's effect on COVID-19 outcomes is unclear.
research Proposing Vascepa (Icosapent Ethyl) as Supplemental Treatment Targeting the Underlying Causes of Persistent, Post-Viral Symptoms Associated with COVID-19: A Case Series
Icosapent ethyl may help treat long-lasting symptoms after COVID-19.
research Significant improvement with ivarmacitinib after suboptimal response to tofacitinib in severe alopecia areata: a case report and literature review
Ivarmacitinib significantly improved hair regrowth in severe alopecia areata after tofacitinib was less effective.
research Simultaneous HBV Reactivation and Hair Discoloration Under Secukinumab Treatment.
Secukinumab treatment may cause HBV reactivation and hair discoloration.
research Treatment of alopecia universalis with topical Janus kinase inhibitors – a double blind, placebo, and active controlled pilot study
Topical JAK inhibitors may help treat alopecia universalis by promoting hair regrowth.
research Budesonide for maintenance of remission in Crohn's disease
Budesonide is not effective for maintaining remission in Crohn's disease beyond three months.
research Translational Positioning of Janus Kinase (JAK) Inhibitors in Alopecia Areata
JAK inhibitors may help treat Alopecia Areata but need careful monitoring due to side effects.
research Alopecia Universalis Successfully Treated With Adalimumab
A woman with severe hair loss was successfully treated with the drug adalimumab.
research INIBIDORES DA JANUS QUINASE PARA O TRATAMENTO DA ALOPECIA AREATA
JAK inhibitors effectively treat severe alopecia areata with manageable side effects.
research Genomic and phenotypic characterization of Investigator Global Assessment (IGA) scale-based endotypes in atopic dermatitis
Different types of atopic dermatitis were linked to specific genetic and immune changes, suggesting that severe cases might need stronger immune-targeting treatments.
research Successful treatment of alopecia universalis with abrocitinib: a case report
Abrocitinib may effectively treat stubborn alopecia universalis.
research 294 Extensive alopecia areata is reversed by IL-12/23p40 cytokine antagonism
Blocking certain proteins can significantly regrow hair in severe alopecia areata.
research Resistant alopecia areata treated with tofacitinib
Tofacitinib can be effective in treating hair loss caused by alopecia areata.